Prediction of Preterm Delivery by Serum Ischemia Modified Albumin, Biglycan and Decorin Levels in Women With Threatened Preterm Labour

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

51 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-01

Study Completion Date

2021-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the levels of ischemia modified albumin, biglycan and decorin in the serums of pregnant women hospitalized for preterm labor will be examined. Their serum levels will be compared between women having preterm and term delivery. Their accuracy will be asessed in predicting preterm birth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

NCT06416995

Preeclampsia Gestational Hypertension Gestational Diabetes +2 more

RECRUITING

Maternal Serum Amyloid A Levels in Pregnancies Complicated With Preterm Labour.

NCT03205020

Preterm Labor

UNKNOWN

Maternal Serum Homocysteine Levels and Uterine Artery Pulsatility Indices in Preterm Labor

NCT03440281

Preterm Labor

COMPLETED

Early Onset Preeclampsia and Nectin-4

NCT05098691

Pre-Eclampsia Early Onset Preeclampsia Oxidative Stress +1 more

COMPLETED

PRETERM DELİVERY and MYOCINE BINDING PROTEIN C LEVELs

NCT05513768

Preterm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will include 90 singleton pregnant women between the ages of 18 and 42 and gestational ages of 24 and 37 weeks.

Inclusion criteria:

* Singleton pregnancy
* Gestational age between 24 and 37 weeks
* Cervical dilatation less than 3 cm and cervical effacement less than 80%
* Uterine contraction ≥3 times at 30 minutes
* Intact amniotic membrane

Excusion criteria:

* Multiple pregnancy
* Preterm premature rupture of membranes
* Abnormal placentation (such as placenta previa)
* Uterin anomaly
* Maternal heart disease
* Inflammatory or infectious disease
* Preeclampsia
* Fetal growth restriction
* Congenital fetal anomaly
* Polyhydramnios
* Acute chorioamnionitis
* Medically induced preterm delivery

Patients who are hospitalized due to preterm labor will primarily receive bed rest and hydration. If cervical changes persist or if contractions continue after 2 hours after intravenous hydration, tocolytic treatment will be started. Calcium channel blockers will be used as tocolytic drug. Maternal corticosteroid (12 mg intramuscular betamethasone within 24 hours) will be given to accelerate fetal lung development. After 48 hours after steroid administration, tocolysis will be stopped. Demographic datas of the patients will be recorded. Patients will be followed until delivery. The gestational week will be determined according to the last menstrual date and will be confirmed by early ultrasonographic measurements. The gestational week at birth and the time between admission to the hospital and birth will be recorded. Delivery time will be divided into groups within 24 hours, 48 hours, 7 days, 14 days, and ≤37 weeks after admission. Mode of delivery, baby's birth weight, APGAR score will be recorded.

Venous blood samples will be taken from patients before medication. Serum samples will be stored in the cooler set to -80 °C until analysis. Levels of ischemia-modified albumin, biglycan and decorin levels will be examined by enzyme-linked immunosorbent assay (ELISA) method.

Statistical analysis:

After the assessment of the data, the variables between two groups will be compared by Mann Whitney U test, Student T test, Fisher Exact Test, Chi-Square Analysis. Regression model will be conducted in order to estimate the probability of the preterm birth. A value of p \< 0.05 will be considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Preterm delivery

Pregnant women who give birth before 37th gestational week

Serum sample analysis

Intervention Type DIAGNOSTIC_TEST

Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels

Term delivery

Pregnant women who will give birth 37th and after gestational week

Serum sample analysis

Intervention Type DIAGNOSTIC_TEST

Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum sample analysis

Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton pregnancy
* Gestational age is between 24-37 weeks
* Cervical dilatation less than 3 cm and cervical effacement less than 80%
* Uterine contraction ≥3 times at 30 minutes
* Intact amniotic membrane

Exclusion Criteria

* Multiple pregnancy
* Preterm premature rupture of membranes
* Abnormal placentation (such as placenta previa)
* Uterine anomaly
* Maternal heart disease
* Inflammatory or infectious disease
* Preeclampsia
* Fetal growth restriction
* Congenital fetal anomaly
* Polyhydramnios
* Acute chorioamnionitis
* Medically induced preterm delivery

Minimum Eligible Age

18 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No